Stability testing of commercially manufactured batches (GMP) of the Tad-Fin Combination Tablet required for submission of a New Drug Application (NDA) is in progress.
The Company has also requested a Pre-NDA meeting with
Tad-Fin Combination Tablet combines two of the most popular medicines, tadalafil and finasteride, that are currently prescribed separately to treat lower urinary tract symptoms caused by an enlarged prostate also known as BPH. The co-administration of tadalafil and finasteride has been shown clinically to be more efficacious in treating BPH symptoms than either tadalafil or finasteride alone.* Our Tad-Fin Combination Tablet is proprietary and is designed to improve patient compliance and safety.
According to current
“This successful clinical study for Tad-Fin Combination Tablet will allow
Veru is also advancing new drug formulations in its specialty pharmaceutical pipeline addressing unmet medical needs in urology. Tamsulosin DRS granules and Tamsulosin XR capsules are formulations of tamsulosin, the active ingredient in FLOMAX®, which
Veru’s Female Health Company Division markets the FC2 Female Condom / FC2 Internal Condom®, an
*Casabé A et al.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
Press Release Kari Sharp